Clinical Trial Update: A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC [Phase 1]

View source ↗

Summary

Phase 1 study of AMG 119 in relapsed or refractory small cell lung cancer is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AMG 119

Snippet

Sponsor: Amgen | Conditions: Small Cell Lung Cancer | Phase 1 | Status: SUSPENDED